37 CFR 1.834 — Form and format for nucleotide and/ or amino acid sequence submissions as the ‘‘Sequence Listing XML’’ in patent applications filed on or after July 1, 2022
Ninth Edition, Revision 01.2024
- (a) A “Sequence Listing XML” encoded using
Unicode UTF–8, created by any means (
e.g., text
editors, nucleotide/amino acid sequence editors, or other custom
computer programs) in accordance with §§
1.831
through
1.833
, must:
- (1) Have the following
compatibilities:
- (i) Computer compatibility: PC or Mac ®; and
- (ii) Operating system compatibility: MS–DOS ®, MS-Windows ®, Mac OS ®, or Unix ®/Linux ®.
- (2) Be in XML format, where all permitted printable characters (including the space character) and nonprintable (control) characters are defined in paragraph 40 of WIPO Standard ST.26 (incorporated by reference, see § 1.839 ).
- (3) Be named as *.xml, where “*” is one character or a combination of characters limited to upper- or lowercase letters, numbers, hyphens, and underscores, and the name does not exceed 60 characters in total, excluding the extension. No spaces or other types of characters are permitted in the file name.
- (1) Have the following
compatibilities:
- (b) The “Sequence Listing XML” must be in a
single file containing the sequence information and be submitted
either:
- (1) Electronically via the USPTO patent electronic filing system, where the file size must not exceed 100 MB, and file compression is not permitted; or
- (2) On read-only optical disc(s) in
compliance with §
1.52(e)
, where:
- (i) A file that is not compressed must be contained on a single read-only optical disc;
- (ii) The file may be compressed using WinZip ®, 7-Zip, or Unix ®/Linux ® Zip;
- (iii) A compressed file must not be self-extracting; or
- (iv) A compressed XML file that does not fit on a single read-only optical disc may be split into multiple file parts, in accordance with the target read-only optical disc size, and labeled in compliance with § 1.52(e)(5)(vi) ;
- (c)
- (1) Unless paragraph (c)(2) of this
section applies, when the “Sequence Listing XML” required by
§
1.831(a)
is submitted in XML file format via the USPTO patent
electronic filing system or on a read-only optical disc (in
compliance with §
1.52(e)
), then the specification must
contain a statement in a separate paragraph
(
see §
1.77(b)(5)
) that incorporates by
reference the material in the XML file identifying:
- (i) The name of the file;
- (ii) The date of creation; and
- (iii) The size of the file in bytes; or
- (2) If the “Sequence Listing XML” required by § 1.831(a) is submitted in XML file format via the USPTO patent electronic filing system or on a read-only optical disc (in compliance with § 1.52(e) ) for an international application during the international stage, then an incorporation by reference statement of the material in the XML file is not required.
- (1) Unless paragraph (c)(2) of this
section applies, when the “Sequence Listing XML” required by
§
1.831(a)
is submitted in XML file format via the USPTO patent
electronic filing system or on a read-only optical disc (in
compliance with §
1.52(e)
), then the specification must
contain a statement in a separate paragraph
(
see §
1.77(b)(5)
) that incorporates by
reference the material in the XML file identifying:
[Added 87 FR 30806, May, 20, 2022, effective July 1, 2022]
Cited authority
- 37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures
- 37 CFR 1.833 Requirements for a “Sequence Listing XML” for nucleotide and/or amino acid sequences as part of a patent application filed on or after July 1, 2022
- 37 CFR 1.839 Incorporation by reference
- 37 CFR 11.52 Written discovery
- 37 CFR 1.52 Language, paper, writing, margins, read-only optical disc specifications
- 37 CFR 1.77 Arrangement of application elements
Cited by
- 1893.01(a)(1) Submissions Required by 30 Months from the Priority Date
- 1893.01(d) Translation
- 201.04 Provisional Application
- 2412 The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures to Include a Sequence Listing in XML file format
- 2412.01 Overview of the Sequence Rules
- 2412.02 Definition of “Sequence Listing XML”
- 2412.06 The Requirement for Exclusive Conformance; Sequences Presented in Drawing Figures
- 2413 Content of a “Sequence Listing XML” and Form and Format of the “Sequence Listing XML” File
- 2413.03 How to Submit the “Sequence Listing XML”
- 2414 Notification of a Failure to Comply with Sequence Listing Requirements and Amendments Relating to “Sequence Listing XML” Files Under 37 CFR 1.835
- 2414.01 Issuance of a Notice Relating to the Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures
- 2414.02 Amendment to Add an Initial “Sequence Listing XML” under 37 CFR 1.835(a)
- 2414.03 Amendment Adding to, Deleting from, or Replacing Sequence Information in a “Sequence Listing XML” under 37 CFR 1.835(b)
- 2414.04 Translation of “Sequence Listing XML” is Not an Amended “Sequence Listing XML” under 37 CFR 1.835(b)
- 2414.05 Notifications for Failure to Submit a “Sequence Listing XML” in an International Application under the PCT to be Searched by the United States International Searching Authority or Examined by International Preliminary Examination Authority
- 2415.02 Provisional Applications Containing Disclosures of Nucleotides and/or Amino Acids, Compliance with 37 CFR 1.831-1.834
- 2416 Form Paragraphs
- 2417 Helpful Hints for Sequence Rules Compliance under WIPO Standard ST.26
- 506 Completeness of Original Application
- 601.01 Complete Application
- 608.01 Specification
- 608.05 “Sequence Listing,” “Large Tables,” or “Computer Program Listing Appendix” Submitted in ASCII Plain Text or a “Sequence Listing XML” Submitted as XML File Text
- 608.05(c) Submissions of Biological Sequence Listings
- 37 CFR 1.52 Language, paper, writing, margins, read-only optical disc specifications
- 37 CFR 1.53 Application number, filing date, and completion of application
- 37 CFR 1.495 Entering the national stage in the United States of America
- 37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures
- 37 CFR 1.835 Amendment to add or replace a “Sequence Listing XML” in patent applications filed on or after July 1, 2022
- 37 CFR 1.839 Incorporation by reference